Array BioPharma

NASDAQ: ARRY
$47.85
+$0.00 (+0.0%)
Closing price July 30, 2019
Stocks were indicated to open higher on Tuesday after a small gain in the Dow and S&P 500 on Monday. It may be the summer, but investors need to be considering how they want their portfolios and...
Array BioPharma shares shot up on Monday after the firm announced that it would be acquired by Pfizer in an all cash transaction. The boards of directors of both companies have approved the merger...
Top hedge funds now are bullish on these four red-hot price momentum stocks, according to a new Jefferies research report.
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
These two biotech and two tech stocks not only have big upside potential, but they are priced right for investors looking for good entry points.
Array BioPharma saw its shares turn negative early on Thursday after the firm announced a secondary offering.
The top analyst upgrades, downgrades and other research calls from Monday include GrubHub, Kroger, Newell Brands, Seagate, Snap, Sony, WEX and FireEye.
Array BioPharma has announced the submission to the FDA of two New Drug Applications to support the use of the combination of binimetinib and encorafenib for the treatment of patients with melanoma.
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
The top analyst upgrades, downgrades and initiations include Alcoa, Altria, Ford, GoPro, NVIDIA, International Paper and Transocean.
The top analyst upgrades, downgrades and initiations seen on Monday include American Express, Barclays, DuPont, NetApp, Plains All American, Viacom and Disney.
Small cap stocks have not held up as well lately, but they are where investors can still find some potentially uncovered gems and extreme value.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Agrium, Array BioPharma, Encana, GoPro and 3D Systems.
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.